- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.11. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 29.10. | Pre-market Movers: GlycoMimetics, BIO-key International, Lixte Biotechnology, Shuttle Pharmaceuticals, Profire Energy | 387 | AFX News | NORWALK (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.30 A.M. ET).In the Green GlycoMimetics, Inc. (GLYC) is up over 163% at $0.4433.
BIO-key... ► Artikel lesen | |
| 23.10. | Lixte Biotechnology granted extension to meet Nasdaq listing rules | 3 | Investing.com | ||
| 23.10. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| LIXTE BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 23.10. | Lixte Biotechnology files to sell units, no amount given | 14 | Seeking Alpha | ||
| 23.10. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 05.09. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.09. | Lixte Biotechnology Holdings, Inc.: LIXTE Receives U.S. Patent Issue Notification for Immune Oncology | 108 | GlobeNewswire (Europe) | Patent Covers Combining LIXTE's LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW)... ► Artikel lesen | |
| 26.08. | Lixte Biotechnology Holdings, Inc.: First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company | 112 | GlobeNewswire (Europe) | PASADENA, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) ("LIXTE" or the "Company"), today announced the dosing of the first patient in a new... ► Artikel lesen | |
| 23.08. | Lixte Biotechnology faces Nasdaq delisting over equity shortfall | 2 | Investing.com | ||
| 19.08. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.08. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Provides Update On Recent Activities and Developments | 265 | GlobeNewswire (Europe) | -Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial by Major Pharma Company- -Distinguished Oncologist Jan Schellens Joins LIXTE as Chief Medical Officer- -Preclinical... ► Artikel lesen | |
| 15.08. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Holdings to Present at Two Investor Conferences | 1 | GlobeNewswire (USA) | ||
| 15.08. | Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event | 252 | ACCESSWIRE | NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing... ► Artikel lesen | |
| 08.08. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.07. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.06. | Lixte, Roche, Netherlands Cancer Institute Collaborate For Colon Cancer Trial; Stock Up | 468 | AFX News | SOUTH SAN FRANCISCO (dpa-AFX) - Lixte Biotechnology Holdings, Inc. (LIXT), Friday announced a partnership with Swiss healthcare company Roche Holding AG (RHHBY) and the Netherlands Cancer Institute... ► Artikel lesen | |
| 14.06. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial | 249 | GlobeNewswire (Europe) | Clinical trial to test recent findings that show LIXTE's lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 14.06. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.06. | Lixte Biotechnology Holdings, Inc.: Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System | 1 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 3,980 | +5,43 % | Inovio Pharmaceuticals Inc. Q3 Loss Narrows | WASHINGTON (dpa-AFX) - Inovio Pharmaceuticals Inc. (INO) reported Loss for third quarter that decreased from last yearThe company's earnings totaled -$25.17 million, or -$0.89 per share. This... ► Artikel lesen | |
| OCUGEN | 0,888 | +2,01 % | Ocugen Receives Orphan Medicinal Product Designation From EMA For OCU410ST | ||
| MAINZ BIOMED | 0,205 | -2,61 % | Mainz Biomed und Thermo Fisher Scientific unterzeichnen Kooperationsvereinbarung | ||
| VIKING THERAPEUTICS | 49,770 | +1,74 % | Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs | ||
| IMMUNITYBIO | 4,779 | +3,31 % | ImmunityBio geht Partnerschaft mit nCartes zur Optimierung klinischer Studien ein | ||
| MARINOMED BIOTECH | 8,360 | -7,73 % | EQS-Adhoc: Marinomed Biotech AG: Marinomed gibt einstimmige Zustimmung der Gläubiger zum Sanierungsplan bekannt | EQS-Ad-hoc: Marinomed Biotech AG / Schlagwort(e): Insolvenz
Marinomed Biotech AG gibt einstimmige Zustimmung der Gläubiger zum Sanierungsplan bekannt
14.11.2024 / 14:34 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| ORAGENICS | 0,286 | 0,00 % | OGEN-Aktie stürzt auf 52-Wochen-Tief von 0,28 US-Dollar | ||
| FRESH TRACKS THERAPEUTICS | 0,730 | 0,00 % | Fresh Tracks Therapeutics, Inc.: Fresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of Company | ||
| RECURSION PHARMACEUTICALS | 5,735 | -5,05 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| FIBROGEN | 0,319 | -3,54 % | FibroGen, Inc.: FibroGen Reports Third Quarter 2024 Financial Results | Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with... ► Artikel lesen | |
| REVIVE THERAPEUTICS | 0,001 | 0,00 % | Revive Therapeutics Ltd.: Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections | TORONTO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research... ► Artikel lesen | |
| BIOLINERX | 0,356 | -31,54 % | BioLineRx inks licensing deal, share purchase agreement | ||
| RADIUS HEALTH | - | - | Radius Health, Inc. (NASDAQ:RDUS) Q4 2024 Earnings Call Transcript | ||
| CAPRICOR | 16,660 | -7,24 % | Capricor wins key EU designations for the lead asset | ||
| MARKER THERAPEUTICS | 2,700 | -5,59 % | Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates | HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for... ► Artikel lesen |
LIXTE BIOTECHNOLOGY HOLDINGS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,480 Euro und damit -0,67 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIXTE BIOTECHNOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.
